Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions

Hepatic Impairment

Interventions

DRUG

Quizartinib

Participants will receive a single oral dose of 30 mg

Trial Locations (3)

RECRUITING

Clinical Pharmacology of Miami, LLC, Miami

RECRUITING

Advanced Pharma, Miami

RECRUITING

GCP Research, St. Petersburg